SMLEREVISE

Gastroesophageal Reflux Disease

Medically Reviewed by Dr. M. Salar Raza | Official SCFHS 2026 Blueprint

Clinical Pathway

Gastroesophageal Reflux Disease (GERD) is a chronic digestive condition characterized by the backward flow of stomach acid or bile into the esophagus, causing irritation and inflammation. This reflux occurs when the lower esophageal sphincter (LES) weakens or relaxes inappropriately, failing to prevent gastric contents from returning to the food pipe. Treatment typically begins with lifestyle modifications such as dietary changes (avoiding trigger foods), weight loss, and elevating the head of the bed. Pharmacological interventions include antacids for immediate relief, H2-receptor blockers to reduce acid production, and proton pump inhibitors (PPIs) as the most effective agents for sustained acid suppression and healing. For severe or refractory cases, surgical options like fundoplication may be considered to reinforce the lower esophageal sphincter. The hallmark symptom is heartburn, a burning sensation in the chest that often worsens after eating, at night, or when lying down. Other common symptoms include regurgitation of food or sour liquid, chest pain, dysphagia (difficulty swallowing), chronic cough, hoarseness, and feeling a lump in the throat (globus sensation). Less common symptoms can include nausea, bad breath, or dental erosion.

Clinical Reasoning

The primary mechanism of GERD involves the dysfunction of the lower esophageal sphincter (LES), a muscular valve that normally prevents the reflux of stomach contents. When the LES relaxes inappropriately, is inherently weak, or is displaced (e.g., by a hiatal hernia), it allows acidic gastric juice and sometimes bile to flow back into the esophagus. This repeated exposure to irritating substances damages the esophageal mucosa, leading to inflammation and typical symptoms. With appropriate lifestyle adjustments and medical management, GERD is generally well-controlled, and symptoms can be significantly reduced or eliminated, allowing most individuals to live normal lives. However, chronic uncontrolled GERD can lead to complications such as esophagitis, esophageal stricture, Barrett's esophagus (a precancerous condition), and, rarely, esophageal adenocarcinoma. Obesity,Hiatal hernia,Pregnancy,Smoking,Consumption of certain foods (e.g., fatty foods, caffeine, alcohol, spicy foods),Certain medications (e.g., NSAIDs, some calcium channel blockers)

Sample MCQ

A 34-year-old man presents with persistent symptoms of gastroesophageal reflux disease (GERD) despite daily treatment with esomeprazole 20 mg. He reports mild improvement but continues to experience nocturnal acid breakthrough, characterized by waking with a sour taste in his mouth. He confirms strict adherence to his prescribed medication regimen. Physical examination reveals no remarkable findings. Which of the following is the most appropriate management for this patient?

  • ASwitch to pantoprazole.
  • BPerform upper endoscopy.
  • CInitiate *Helicobacter pylori* eradication therapy.
  • DIncrease the dose of esomeprazole.

Correct Answer: D

### TLDR The patient experiences persistent GERD with nocturnal acid breakthrough despite daily esomeprazole, indicating suboptimal acid suppression. The most appropriate immediate next step is to optimize the current proton pump inhibitor (PPI) therapy by increasing its dose. ### Comparison Table | Option | Mechanism | Clinical Nuance | Key Distinction | |---|---|---|---| | Switch to pantoprazole | Another PPI, inhibits proton pump. | Equipotent to esomeprazole in acid suppression. | Not likely to improve partial response. | | Perform upper endoscopy | Visualizes upper GI tract for pathology. | Indicated for alarm symptoms or refractory GERD. | No alarm symptoms; PPI optimization precedes. | | Initiate *Helicobacter pylori* eradication therapy | Eliminates *H. pylori* infection. | Primarily treats peptic ulcer, not GERD. | No indication for *H. pylori* testing/treatment. | | **Increase the dose of esomeprazole** | Enhances acid suppression by PPI. | Standard next step for partial PPI response. | Optimizes current effective therapy for symptoms. | ### Detailed Breakdown This patient presents with persistent GERD symptoms, specifically nocturnal acid breakthrough, despite strict adherence to daily esomeprazole 20 mg. This indicates that the current level of acid suppression is inadequate. In the absence of alarm symptoms (e.g., dysphagia, odynophagia, weight loss, anemia, GI bleeding), the initial management strategy for partial response to a proton pump inhibitor (PPI) is to optimize the PPI regimen. **Increasing the dose of esomeprazole** is the most appropriate next step. Esomeprazole is a potent PPI, and increasing the dose (e.g., to 40 mg daily or 20 mg twice daily) aims to achieve more profound and sustained acid suppression, which can resolve nocturnal acid breakthrough. This is a standard escalation strategy before considering other interventions. Let's consider why the other options are less appropriate: * **Switching to pantoprazole** is generally not recommended as the first step for PPI non-response. All PPIs are considered equipotent when administered at appropriate doses, and there is usually no clinical advantage in switching from one PPI to another if the patient has only had a partial response. * **Performing an upper endoscopy** is indicated for patients with alarm symptoms (such as dysphagia, odynophagia, unintentional weight loss, GI bleeding, anemia), long-standing GERD unresponsive to optimized PPI therapy, or to rule out complications like Barrett's esophagus or malignancy. This patient does not report alarm symptoms, and their PPI therapy has not yet been optimized. * **Initiating *Helicobacter pylori* eradication therapy** is not indicated in this scenario. *H. pylori* infection is not a primary cause of GERD, and treating it typically does not alleviate GERD symptoms. There are no clinical indications (e.g., peptic ulcer disease, gastric MALT lymphoma) to suggest *H. pylori* testing or eradication is necessary for this patient's presentation.

Master the 2026 SMLE

Explore more clinical protocols in the SMLEREVISE Clinical Knowledge Library.

Try the QBank & Scaled Mocks